Skip to main content
A. Bar-Gil Shitrit on Muck Rack

A. Bar-Gil Shitrit

As seen in: Color Research & Application
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with A. Bar-Gil

Contact A. Bar-Gil, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab

|
By S. Paul, B. Ungar, U. Kopylov, T. Engel, M. Yavzori, E. Fudim, O. Picard, A. Lang, N. Williet, Y. Chowers, A. Bar-Gil Shitrit, R. Eliakim, S. Ben-Horin, X. Roblin
| Color Research & Application Verified
Anti-adalimumab antibodies (AAA) are associated with loss of clinical response (LOR). Addition of an immunomodulator has been shown to reverse immunogenicity and regain response with infliximab monotherapy. Similar data on adalimumab are lacking. To study the impact of immunomodulator addition on the emergence of AAA and LOR among adalimumab therapy patients.
Open in Who Shared Issue with article?
See all 1 articles